BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have been assigned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $390.00.

A number of brokerages have recently commented on ONC. Wolfe Research initiated coverage on BeOne Medicines in a report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price target on the stock. Royal Bank Of Canada upped their target price on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday. Guggenheim upped their target price on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Barclays upped their target price on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, Jefferies Financial Group lowered BeOne Medicines from a “buy” rating to a “hold” rating and dropped their target price for the stock from $420.00 to $290.00 in a report on Monday, March 16th.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $274.69 on Friday. The firm has a market cap of $30.14 billion, a price-to-earnings ratio of 61.45 and a beta of 0.49. The stock’s 50-day moving average is $301.97 and its 200-day moving average is $320.17. BeOne Medicines has a one year low of $239.25 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities analysts predict that BeOne Medicines will post 5.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Corazon (Corsee) D. Sanders sold 212 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $309.59, for a total transaction of $65,633.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Chan Henry Lee sold 332 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $310.72, for a total value of $103,159.04. Following the sale, the senior vice president owned 101 shares in the company, valued at $31,382.72. The trade was a 76.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,641 shares of company stock worth $505,791. Insiders own 6.19% of the company’s stock.

Institutional Trading of BeOne Medicines

Several institutional investors and hedge funds have recently bought and sold shares of ONC. EFG International AG bought a new stake in BeOne Medicines during the fourth quarter worth about $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines during the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines during the second quarter worth approximately $35,000. CWM LLC increased its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the last quarter. Finally, Group One Trading LLC acquired a new position in BeOne Medicines during the fourth quarter worth approximately $61,000. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.